Delivery Order SPE2DB22D2211-SPE2DB25FSDLN
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Bridion 200 mg/2 mL vials with a contract value of $27,818.98. This firm fixed-price delivery order, which is expected to be completed by August 26, 2025, represents a single transaction under AmerisourceBergen's larger pharmaceutical supply agreement. The award was competitively awarded with no set-aside designation and will be performed at the company's corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $12,673.71 to AmerisourceBergen Drug Corp for the supply of Bridion 500 mg/5 ml vials on August 21, 2025. The contract is structured as a firm fixed price delivery order with an ultimate completion date of August 22, 2025, and represents a non-competitive, non-set-aside award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $37,940.60 to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Bridion 500 mg/5 mL vials. This firm fixed-price delivery order, with an ultimate completion date of August 14, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The contract falls under the company's...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order on July 29, 2025, for Bridion 500 mg/5 mL vials, with a ceiling value of $35,252.62 under firm fixed-price terms. The contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. This competitively awarded, non-set-aside delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Bridion 200 mg/2 ml vials with a ceiling value of $58,610.19 under firm fixed price terms. This non-set-aside competitive award is categorized as a delivery order, with an ultimate completion date of August 21, 2025. AmerisourceBergen will perform the work at its corporate office location in Conshohocken, Pennsylvania. Bridion is a neuromuscular reversal agent used in...
- The Defense Logistics Agency awarded a delivery order valued at $6,129.70 to AmerisourceBergen Drug Corp for Bridion 200 mg/2 ml vials on July 25, 2025, with an ultimate completion date of July 28, 2025. This competitively awarded, firm fixed-price delivery order represents a continuation of pharmaceutical supply fulfillment under AmerisourceBergen's broader relationship with the federal government. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, the location of the...
- The Defense Logistics Agency awarded a delivery order valued at $27,945.02 to AmerisourceBergen Drug Corp for the supply of Bridion 200 mg/2 ml vials on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal healthcare...
- The Defense Logistics Agency awarded a delivery order valued at $20,061.21 to AmerisourceBergen Drug Corp for the supply of Bridion 200 mg/2 mL vials on July 23, 2025, with completion scheduled for July 24, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this delivery order from its corporate office location. This...
- The Defense Logistics Agency awarded a delivery order valued at $8,288.57 to AmerisourceBergen Drug Corp for the supply of Bridion 500 mg/5 ml vials on August 15, 2025, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The place of performance is located in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $6,402.73 delivery order to AmerisourceBergen Drug Corp for Bridion 500 mg/5 ml vials on July 21, 2025, with a completion date of July 22, 2025. This competitively awarded, firm fixed-price contract is a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The work will be performed at AmerisourceBergen's corporate office location in...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FSDLNDelivery Order
The Defense Logistics Agency awarded a $18,234.69 delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Bridion 200 mg/2 ml vials. The contract is a firm fixed price, non-set-aside award with an ultimate completion date of August 25, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999.999 billion and runs through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement across the Defense Health Agency and other military healthcare systems. The company was competitively selected to supply pharmaceutical products and medical commodities supporting military healthcare programs globally. Bridion, a neuromuscular blocking agent reversal agent, represents one of the specialized pharmaceutical products within the company's comprehensive portfolio delivered through the DLA's pharmaceutical supply chain to support operational readiness and medical care standards across the Department of Defense.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $18.2k | 8/22/25 |